Martin Frenzel

Martin Frenzel is a seasoned professional in biostatistics with extensive experience in the pharmaceutical industry. Currently serving as Senior Director of Biostatistics at Formation Bio since December 2023, Martin previously worked as a Strategic Consultant at Cytel, where solutions were developed for client challenges in biostatistics. Martin held significant roles at Eli Lilly and Company from 2012 to 2022, including Senior Director of Statistics for the Oncology division, overseeing statistical activities for multiple oncology molecules, and Early Phase Development Team Leader responsible for early phase project strategies. Additionally, Martin contributed as the Asset Lead Statistician for the development of abemaciclib in breast cancer. Early career experience includes an internship at Merck. Academic achievements include a PhD in Statistics and a Bachelor of Science in Mathematics from the University of Nebraska-Lincoln.